Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499 /month or less, regardless of insurance ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...